Premium
Meloxicam in acute UV dermatitis — a pilot study
Author(s) -
Bayerl C.,
Pagung R.,
Jung E. G.
Publication year - 1998
Publication title -
photodermatology, photoimmunology and photomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.736
H-Index - 60
eISSN - 1600-0781
pISSN - 0905-4383
DOI - 10.1111/j.1600-0781.1998.tb00037.x
Subject(s) - meloxicam , medicine , erythema , antagonist , cyclooxygenase , pharmacology , drug , piroxicam , sunburn , anesthesia , dermatology , enzyme , chemistry , biochemistry , receptor , alternative medicine , pathology
The non‐steroidal anti‐inflammatory drug (NSAID) meloxicam is a preferential cyclooxygenase‐2 (COX‐2) antagonist. The UV protective potential of this drug was studied to compare it with the reported beneficial effects of such preferentially COX‐1 specific NSAIDs as indomethacin and acetylsalicylic acid in the literature. In a pilot study (open‐label, non‐randomized, non‐controlled, unblinded), 10 patients received UV irradiation with the minimal erythema dose (MED), first with meloxicam (7.5 mg/die) to reduce post‐operative pain and second without ingestion of meloxicam. The factor of UV protection was evaluated. In six of ten patients meloxicam showed no benefit, whereas four of ten patients had a 1.3‐ up to 3‐fold UV protection. In this study, the benefit in UV protection of meloxicam as a prefential COX‐2 antagonist was not above the reported benefit of the “old” COX‐1 inhibiting NSAIDS.